# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Additional data continues to support highly differentiated profile for FB102 in celiac diseaseForte Biosciences, Inc. (www.fort...
Guggenheim analyst Yatin Suneja initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and announces Price ...
Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $61 price target.
Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related ...